JANUARY 10, 2020, New York
Paige, the leader in computational pathology transforming the diagnosis and treatment of cancer, welcomes Dr. R. Martin Chavez to its board of directors. Chavez joins Paige’s board after recently retiring from Goldman Sachs, where he served 19 years in multiple roles – including CIO, CFO, and Co-Head of Securities. He’s been credited as one of the key figures in elevating the roles of engineering and data science, both at Goldman Sachs and in the financial services sector more broadly. In this hands-on role at Paige, he will be working with the Company to help create a similar transformation in healthcare.
Following Paige’s recent close of its $45 million Series B funding round, Chavez will be instrumental in working with key executives as they grow the Company’s product portfolio, commercialize their solutions and expand into biopharma services and new geographies.
“I’m thrilled at the opportunity to put my experience at the crossroads of math, data, software, and machine learning to work for the crucial mission of revolutionizing cancer prognosis and treatment,” said Chavez, who holds a Ph.D in Medical Information Sciences from Stanford University. “I’m looking forward to joining Paige’s team in driving forward computational models for human tissue, while building a world-class culture of engineering, data science, and clinical decision analysis.”
Prior to joining Goldman Sachs, Chavez was CEO and co-founder of Kiodex, acquired by Sungard in 2004. He was also Chief Technology Officer and co-founder of Quorum Software Systems. He currently serves on the Board of Overseers of Harvard University, the Stanford Medicine Board of Fellows and the Board of Trustees of the Institute for Advanced Study. He was one of the key figures in elevating the roles of engineering and data science, both at Goldman Sachs and on Wall Street, more broadly.
“I couldn’t be more excited to welcome Marty to our active and influential board of directors,” said Leo Grady, CEO at Paige. “He has been enormously successful as an entrepreneur and leader. At Paige, we intend to transform cancer care in the same way that Marty transformed finance, which will have a far-reaching impact on clinical medicine and drug development. Marty will be very hands on with us, along with Jim Breyer and our other board members, to build a truly transformative healthcare company.”
Chavez joins the Paige board of directors after a stellar year of significant momentum for the Company. Leo Grady, CEO, joined Paige in February 2019 and the Company went on to receive the first FDA breakthrough designation in the same month. Paige’s technology was published in top peer-reviewed journals, highlighting significant advances is building robust AI solutions based on pathology data. The Company ended the year by receiving the first CE mark for a computational pathology solution, Paige Prostate, and announced a partnership with Philips to distribute the product. To close out 2019, the company announced its series B funding and is now working to expand its offerings for clinical pathology practices and the biopharma industry.
Paige was founded in 2017 by world leaders in Pathology and AI at Memorial Sloan Kettering. The Company builds powerful, clinical-grade computational technologies to transform diagnosis, treatment, biomarker discovery and drug development for cancer. With AI positioned to open a new future of cancer care, Paige has created an AI-native ecosystem that enables pathology teams to achieve higher quality, faster throughput and lower cost diagnoses and treatment recommendations. Additionally, Paige accelerates new biomarker discovery and its platform is designed to generate new insights into pathways and drug efficacy. Paige is committed to delivering the technology in a way that integrates seamlessly with hospital and laboratory workflow systems and ensures safety, accuracy, security and data privacy.